RecruitingNCT07523048
Dextromethorphan-bupropion for depression
Researchers are studying how the medication affects brain activity related to reward processing in adults with depression.
Medication + MRIAges 18–65Canada
Understand this study
What is this study about?
Researchers are studying how dextromethorphan-bupropion affects brain responses related to reward processing in adults with depression.
Who could participate?
Adults aged 18–65 with a current moderate to severe depressive episode without psychotic features and fewer than five previous adequate medication trials for depression. MRI eligibility, English reading and speaking, internet access and other criteria apply.
What will I do during this study?
Take the study medication for 14 days and have functional MRI (magnetic resonance imaging) scans before and after treatment, while completing a reward task. The scans measure brain activity; they are not the treatment.
- Listed locations
- TorontoSee all locations and recruitment
- Treatment duration
- 14 days of medication
- Visits and schedule
- MRI (magnetic resonance imaging) before treatment on Day 1 and after treatment on Day 14; total participation time is not established here.
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
Your treatment and care
The protocol excludes several current medicines, including antidepressants and MAO inhibitors. Any treatment changes need to be discussed with the research team and your usual prescriber.
Risks and eligibility restrictions
Listed exclusions include seizure conditions, current or past anorexia or bulimia, certain medication interactions, and MRI contraindications such as some implanted devices. These are selected restrictions, not a complete risk assessment.
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 21, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 30
- Sponsor
- Roger McIntyre
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07523048
- Official title
Show the full official title
Two-Week, Open-Label, Exploratory Neuroimaging Study Evaluating the Effect of Dextromethorphan-HBr Bupropion-HCl on Striatal Reactivity During Reward Processing in Adults With Major Depressive Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Toronto
Interested in joining this study?
Questions about this study
What is this study about?
This study investigates how dextromethorphan-bupropion affects the brain’s response to rewards in adults with depression.
What will I need to do?
You will have brain scans and take study medication.
Who is behind this study?
The study sponsor is Roger McIntyre.
Does this study involve medication?
Yes. The study involves medication, including dextromethorphan-bupropion.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
